Latest News

Newly identified antibody has potential to stop, reverse pulmonary arterial hypertension

Scientists at the University of Sheffield, working in collaboration with drug and vaccine developer Kymab Ltd, Cambridge, have identified a novel antibody that has the potential to become a new treatment for pulmonary arterial hypertension (PAH).

Source link

Related posts

Nerve stimulation may benefit women with fibromyalgia


Lupin partners with Abbvie to develop and commercialize new targeted oncology treatments


Catheter ablation reduces dementia risk in A-Fib, heart disease patients more than medications


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy